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Transfusions for patients with sickle cell 




Children’s Hospital Boston is a large pediatric medical 
center with 390 inpatient beds and several outpatient clinics. 
All transfusions of hospitalized patients with sickle cell disease 
(SCD) occur at the main hospital site in Boston. Outpatient 
transfusions take place at the main site in Boston and at a 
satellite clinic in Waltham, Massachusetts, which is about a 
25-minute drive from the main Boston site. Approximately 
180 patients with SCD are treated by Children’s Hospital 
Boston annually. These patients are predominantly children. 
At age 18 to 21 years, patients are transitioned to an adjacent 
hospital that treats adult patients with SCD.
Red blood cell (RBC) units for transfusions at both sites 
are provided by one blood bank located at the main hospital 
in Boston. Children’s Hospital Boston blood bank includes 
a blood donor center, transfusion service laboratory, and 
therapeutic apheresis unit. The apheresis unit performs 
RBC exchange transfusions for emergencies and for chronic 
transfusion therapy. Currently, approximately two RBC 
exchange procedures are performed each week. The blood 
donor center collects blood in a fixed site blood donor center 
adjacent to the main hospital lobby and from a bloodmobile 
that collects blood throughout eastern Massachusetts. The 
blood donor center collects enough blood to supply most of the 
RBC unit needs for Children’s Hospital Boston. Although not a 
full immunohematology reference laboratory, the transfusion 
service laboratory performs many immunohematology 
laboratory tests and also has a molecular testing area that 
performs single-nucleotide polymorphism (SNP) analysis 
using the BioArray Solutions System of Immucor Corporation 
(Norcross, GA). Genotyping is performed on a large proportion 
of the blood donors.
Transfusion Protocol
In addition to ABO and D, SCD patients are prospectively 
matched for K, C, and E. The treating hematologist sends a 
sample of blood from each patient with SCD who is at least 1 
year old for the blood bank to determine the patient’s phenotype 
for these antigens using serologic methods. Patients lacking K, 
C, or E antigens will receive RBC units lacking those antigens. 
No attempt is made to match for k, c, or e. Having a large 
number of RBC units genotyped facilitates rapid identification 
of appropriate RBC units, but genotyping is used as a screening 
test with serology used to confirm that specific antigens are 
lacking on RBC units.
Genotyping and serologic information are entered into 
blood donor records, and donors who are particularly useful 
for frequently transfused patients with SCD are targeted for 
extra recruitment efforts. This is done regardless of donor race. 
Indeed, the blood donor center does not track the race of the 
blood donors.
The blood needs for patients with SCD have increased in 
recent years as more patients have been chronically transfused 
based on findings of the STOP and STOP II trials.1,2 This has 
led to more patients with iron overload and subsequently 
more patients transfused by RBC apheresis to reduce the iron 
burden.3 Although RBC apheresis reduces the iron burden, it 
also increases the number of RBC units used by the patients 
and hence has increased the demand on our blood bank. 
The Children’s Hospital Boston blood donor center has made 
initial attempts to have blood drives at locations with high 
proportions of African Americans, but these efforts have not 
met the increased demand and the hospital has had to import 
RBC units for some of these patients.
RBC Selection Protocol
Children’s Hospital Boston will use RBC units of any 
age for patients with SCD unless they also are in a category 
of patients who receive fresher RBC units, such as infants 
undergoing surgery. Except in emergencies, all RBC and 
platelet units at Children’s Hospital Boston are irradiated, 
and patients with SCD receive irradiated units just as all 
other patients do. Patients with SCD receive RBC units that 
are negative for hemoglobin S (HbS). Although the BioArray 
molecular system tests for the HbS gene, the Sickledex (Streck, 
Inc., Omaha, NE) test is used to confirm that an RBC unit is 
negative for HbS.
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All RBC and platelet units at Children’s Hospital Boston 
are leukocyte reduced and considered cytomegalovirus (CMV) 
safe. In addition, some units are known to be serologically 
negative for CMV antibodies. Such units are preferentially 
provided to patients at higher risk for CMV infection such 
as hematopoietic progenitor cell transplant patients who are 
CMV negative. Patients with SCD are not considered at high 
risk for CMV disease and so do not preferentially receive CMV 
serologically negative units.
Children’s Hospital Boston plans to test its RBC units 
for babesiosis using investigational tests and will attempt to 
have its entire RBC inventory tested for this disease. This will 
likely not be possible at all times. When there is an inventory of 
Babesia-tested and -untested RBC units, Babesia-tested RBC 
units will be preferentially provided to patients with SCD.
Emergency Protocols
If blood is emergently needed, blood untested for HbS 
may be transfused, at the discretion of the blood bank 
physician. Additionally, matching for the C, E, or K antigens 
may be skipped at the discretion of the blood bank physician. 
If no compatible blood is available, then Children’s Hospital 
Boston will attempt to procure RBC units lacking the 
necessary antigens from other sources. In these situations, 
the blood bank physician will usually be in communication 
with the treating hematologist. If no crossmatch-compatible 
RBC units are available anywhere, or if the RBC units are 
needed before they arrive at the hospital, incompatible RBC 
units may be transfused. However, if the patient has clinically 
significant antibodies, for example to antigens in the Rh 
system, or if the patient has developed hyperhemolysis, then 
the recommendation may be to avoid the transfusion. Indeed, 
transfusions have successfully been avoided by providing 
supportive care for patients with SCD who have very low blood 
hemoglobin concentrations for extended periods of time.
If a patient has a warm autoantibody, underlying 
alloantibodies are identified with the use of adsorption 
techniques. In addition, the patient’s predicted extended 
phenotype is determined by DNA methods. Such a patient is 
preferentially transfused with genotyped RBC units matched 
for several antigens. With this protocol, the blood bank knows 
the foreign RBC antigens to which the patient has been exposed 
and hence the potential alloantibodies that may develop.
Genotyping may also be performed on some select patients 
who do not have autoantibodies. These are determined on an 
individual case basis. In general, genotyping may help the 
laboratory investigation in patients with complex serologic test 
results. Also, genotyping can be extremely helpful in patients 
suspected of having Rh variant alleles based on serologic 
results. In these cases, Children’s Hospital Boston will generally 
send out the specimen for further molecular characterization 
that cannot be provided by the standard BioArray chip.
Protocol Outcomes
Antibody development has generally been manageable 
with the protocols used by Children’s Hospital Boston. 
Although we have not directly compared the antibodies 
developed under this protocol with antibodies that developed 
without D, C, E, and K matching, very few antibodies to these 
antigens have developed. The few patients who have developed 
antibodies in the Rh system usually have Rh variants or were 
transfused elsewhere. Specifically, a few patients developed 
antibodies that appeared to have a relative or absolute 
specificity for e antigen, and these patients were subsequently 
found to have variant RHCE alleles. One patient with SCD 
exhibited anti-D. Subsequent testing suggested that this 
patient had a partial RHD gene that was not detected before 
his transfusion of D+ RBCs. No patients with SCD in the past 
several years have developed panreactive autoantibodies. 
At least two patients have developed hyperhemolysis 
syndrome. The patients who developed hyperhemolysis did 
not have detectable autoantibodies, and one of the patients 
had no detectable antibodies against minor RBC antigens 
(negative antibody screen). The blood bank almost always 
has sufficient RBC inventory to avoid incompatibilities with 
any alloantibodies that have developed in  patients with SCD, 
and few  of these patients have developed autoantibodies. The 
main difficulties have been with patients with unusual RH 
alleles, some of whom have developed antibodies reactive with 
the Rh proteins present on most donor units. In rare cases, 
Children’s Hospital Boston has needed to acquire RBC units 
from blood supplies for these patients. Although there are 
significant costs associated with genotyping, this testing has 
aided in the identification of valuable blood donors and greatly 
speeds the process of identifying antigen-negative RBC units. 
This improves the turnaround time, an improvement that is 
especially valuable for  patients with SCD requiring emergent 
transfusions.
Summary
During the past decade, Children’s Hospital Boston 
has had four changes affecting transfusion therapy for SCD 
patients:
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1. A bloodmobile has helped increase blood collections. 
This could allow for more drives at locations with 
many African Americans, but attempts to date have 
not met the growing need.
2. Genotyping has allowed for predicting the extended 
phenotype of many RBC units and patients with 
autoantibodies.
3. Transfusion-transmitted babesiosis cases have 
increased, and Children’s Hospital Boston will soon be 
providing Babesia-tested RBC units.
4. The number of RBC units transfused to patients with 
SCD has increased as a result of studies finding the 
benefits of transfusion therapy in decreasing stroke 
risk. This has significantly impacted the inventory, 
making it difficult and sometimes impossible to 
provide RBC units matched for multiple antigens.
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